News | 06 January 2025
ICMR detects two cases of HMPV in Karnataka through routine surveillance
ICMR will continue to track trends in HMPV circulation throughout the year
ICMR will continue to track trends in HMPV circulation throughout the year
2.92 acre facility will combine tradition and innovation, offering new opportunities for holistic healing, specialized clinics, and skill development to be constructed at a cost of around Rs. 185 crore
The order, part of an international framework agreement is to be executed between February to April, 2025
The acquired hospital is a well-established hospital based out of Model Town, New Delhi
There was no casualty or loss of human life in the incidence
Brings together industry experts to discuss preventive steps to protect pigs from African swine fever and best practises for pig farm management
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences
The President said that there is a need to spread more and more awareness regarding the causes, diagnosis and treatment of cancer
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Subscribe To Our Newsletter & Stay Updated
